Trial Profile
A randomized, open-label, two arm trial to compare the safety and antiviral efficacy of GW433908 [fosamprenavir]/ritonavir QD [daily] to nelfinavir BID [twice daily] when used in combination with abacavir and lamivudine for 48 weeks in antiretroviral therapy naive HIV-1 infected subjects.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Lamivudine/abacavir (Primary) ; Nelfinavir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 20 Oct 2005 New trial record.